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Mutations in genes that control class switch recombination and somatic hypermutation 
during the germinal center (GC) response can cause diverse immune dysfunctions. 
In particular, mutations in CD40LG, CD40, AICDA, or UNG cause hyper-IgM (HIGM) 
syndrome, a heterogeneous group of primary immunodeficiencies. Follicular helper (Tfh) 
and follicular regulatory (Tfr) T cells play a key role in the formation and regulation of 
GCs, but their role in HIGM pathogenesis is still limited. Here, we found that compared 
to CD40 ligand (CD40L)- and activation-induced cytidine deaminase (AICDA)-deficient 
patients, circulating Tfh and Tfr cells were severely compromised in terms of frequency 
and activation phenotype in a child with CD40 deficiency. These findings offer useful 
insight for human Tfh biology, with potential implications for understanding the molecular 
basis of HIGM syndrome caused by mutations in CD40.
Keywords: hyper-IgM syndrome, follicular helper t cells, follicular regulatory t cells, class switch recombination, 
somatic hypermutation, AICDA, CD40LG, CD40
BaCKGRoUND
Hyper-IgM (HIGM) syndromes comprise a group of rare primary immunodeficiencies characterized 
by low or absent IgG and IgA and normal to elevated levels of IgM (1, 2). CD40 ligand (CD40L) 
deficiency is X-linked and the estimated frequency is 2:1,000,000 males (3). Although no data 
are available on the frequency of activation-induced cytidine deaminase (AID) deficiency, this 
Abbreviations: HIGM, hyper-IgM; CSR, class switch recombination; SHM, somatic hypermutation; GC, germinal center; 
AID, activation-induced cytidine deaminase; CD40L, CD40 ligand; UNG, uracil N-glycosylase; HC, healthy control; Tfh, T fol-
licular helper; Treg, T regulatory; Tfr, T follicular regulatory; FDCs, follicular dendritic cells; C3b, complement 3b; TMP–SMZ, 
trimethoprim/sulfamethoxazole; PCP, Pneumocystis carinii pneumonia; HSCT, hematopoietic stem cell transplantation.
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disorder is estimated to affect less than 1:1,000,000 individuals 
(4). In contrast, there are only a few reported cases of CD40 
and uracil N-glycosylase (UNG) deficiencies (5–9).
Patients affected by HIGM present defects in class switch 
recombination and somatic hypermutation, two events that 
take place in germinal centers (GCs) (2–6). These processes 
are compromised in HIGM patients due to impaired cross-talk 
between T and B  cells caused by mutations in CD40LG and 
CD40 or intrinsic B  cell defects due to mutations in AICDA 
and UNG (10, 11). Clinically, affected patients present recurrent 
respiratory and gastrointestinal infections, and in some cases 
autoimmune manifestations (1–3). Patients with mutations in 
CD40L or CD40 are particularly susceptible to Pneumocystis 
carinii pneumonia (PCP) and Cryptosporidium infection (3, 7). 
Autoimmune manifestations may occur in all forms of HIGM, 
although they seem more frequent in AID deficiency (12, 13). 
Two recent studies reported a reduction in the percentage of 
CD4+CD25+FOXP3+ T regulatory cells (Tregs), accompanied by 
an increase in the Th17/Treg cell ratio and Th1/Treg cell ratio in 
CD40L-deficient patients (14, 15). Similarly, patients with muta-
tions in AICDA, but not UNG-deficient patients, displayed Treg 
cells with defective suppressive function (16). These results may 
explain the increased susceptibility to autoimmunity in these 
disorders.
Follicular helper T cells (CXCR5+FOXP3−) (Tfh) and folli-
cular regulatory T cells (CXCR5+FOXP3+) (Tfr) are considered 
key players for the formation and regulation of GCs, respectively 
(17–19). To date, available data regarding these T cell subsets in 
HIGM syndromes are limited and in some cases discordant (16, 
20, 21). Furthermore, studies on Tfh and Tfr cells in humans with 
an extremely rare form of HIGM caused by CD40 deficiency 
are completely lacking. Here, we report for the first time the 
distribution and phenotype of circulating Tfh and Tfr cells in a 
patient with CD40 deficiency and compare them to CD40L and 
AID-deficient patients.
MetHoDs
Clinical Cases and Controls
Ten patients with diagnosis of monogenic HIGM syndromes 
referred from the Pediatrics Clinic, University of Brescia and 
ASST-Spedali Civili of Brescia, Fondazione IRCCS Cà Granda 
Ospedale Maggiore Policlinico, Milan, IRCCS Instituto Giannina 
Gaslini, Genoa and Immuno-rheumatology, II, Regina Margherita 
Hospital, Turin, Italy, were enrolled in the study. All the subjects, 
their parents or guardians provided a written informed consent. 
The study was approved by the local ethics committee (Comitato 
Etico Ospedale San Raffaele, Milano) and performed in accord-
ance with the Declaration of Helsinki.
The study group included one pediatric patient with CD40 
deficiency, three patients with AID deficiency (one adult and 
two pediatric) and six patients with CD40L deficiency [two 
adult and four pediatric (one patient was analyzed in pediatric 
and adult age)]. Clinical characteristics of the study participants 
are shown in Table  1. Seven pediatric (6  months–10  years) 
and nine adult (23–40 years) healthy donors were included as 
controls (HC).
sample Collection and analysis
Peripheral blood mononuclear cells (PBMCs) were isolated by 
density-gradient centrifugation over Lymphoprep (Stemcell) 
from heparinized venous blood and frozen in RPMI (Lonza) 
with addition of 10% DMSO and 25% FBS. PBMCs were then 
thawed in water bath at 37° and stained for flow cytometry with 
superficial antibodies against CD4 (SK3), CD3 (SK7), CD45RA 
(H100), CD19 (4G7), CD14 (TUK4), CD8 (BW135/80), CXCR5 
(RF8B2), PD-1 (eBioJ105), and ICOS (ISA-3) (Ab clones are 
indicated in the parentheses). Cells were fixed and permeabilized 
for intracellular staining with the FOXP3 Transcription Factor 
Staining Buffer Set (eBioscience) and stained with antibodies 
against FOXP3 (259D). Cells were acquired on FACSCantoII 
(BD) and analyzed with FlowJo (Tree Star) software. Mann–
Whitney statistical analysis was performed between HC and 
patient groups with the prism software (San Diego).
ResULts
summary of Case Report
The CD40 deficient patient was born from first-degree consan-
guineous Italian parents. The patient was admitted at the age of 
4 months for severe respiratory distress due to PCP, and subse-
quently re-admitted at the age of 2 years for another pneumonia 
event. During the second infectious episode, immunological 
work-up showed low IgG and IgA with normal IgM serum 
levels and received immunoglobulin replacement treatment and 
trimethoprim/sulfamethoxazole prophylaxis (Table  1). During 
follow-up, the patient presented recurrent respiratory infections. 
The clinical history was complicated by Cryptosporidium infec-
tion at the age of 12 years that led to progressive end-stage liver 
dysfunction. The patient over time developed esophageal varices, 
diffuse abdominal spider naevi with ascitis and severe mucositis 
and became transfusion dependent. Considering the patient’s 
severe clinical course, the parents decided against hematopoietic 
stem cell transplantation. The severity of her clinical conditions 
led to exitus at the age of 16 years (5).
tfh and tfr Cell Frequencies in Human 
CD40 Deficiency
Comparison between pediatric and adult HCs showed differences 
in the percentage of Tfh cells: pediatric HCs had lower frequency 
of Tfh cells within CD4+ T  cells when compared with adult 
HCs (Figures  1A,B), reflecting the expansion of this memory 
T  cell subset with age. Instead, frequencies of Tfr and Treg 
(CXCR5−FOXP3+) cells did not change with age (not shown). 
Since Tfh cells differed significantly between pediatric and adult 
HCs, patients were compared with age-matched HCs. Tfh, Tfr, 
and Treg cells were severely reduced in the child with CD40 
deficiency as compared with healthy children (Figures  1B–E). 
Reduction in Tfh and Treg but not in Tfr cell frequencies were 
also observed in children with CD40L deficiency as compared 
taBLe 1 | Patients’ mutations, clinical characteristics and immunological profile.
patient age 
(years)
sex Genetic 
defect
Mutation CD3+ cells/ 
μl (nv) (34)
CD3+CD4+ cells/ 
μl (nv) (34)
CD3+CD8+ cells/ 
μl (nv) (34)
CD19+ cells/ 
μl (nv) (34)
CD16+CD56+ 
cells/μl  
(nv) (34)
IgG g/l  
(nv) (35)
Iga g/ 
l (nv) (35)
IgM g/l  
(nv) (35)
Clinical manifestations treatment
Pt. 1 15 F CD40 c. 408A>T 
EX5 skipb
2,000 (1,000–2,000) 1,507 (400–2,000) 356 (200–800) 438 (200–600) 302 (100–700) 1.80 (6.4–19) <0.06 (0.6–3) 0.80 (0.6–3) Pneumocystis infection
Cryptosporidium infection
Recurrent respiratory infections
Liver insufficiency
Exitus
IVIG, TMP–SMZ
Pt. 2 31 M AICDA c.441C>Ab; 
p.C147X;
6,267 (600–2,000) 908 (400–1,200) 4,092 (200–800) 136 (100–500) 348 (100–500) <0.35 (6.4–19) <0.06 (0.6–3) 43.90 (0.6–3) Recurrent respiratory infections
Bronchiectasis
Splenomegaly
SCIG
Pt. 3 3 F AICDA c.389A>Cb; 
p.H130P;
2,735 (1,200–4,000) 1,006 (600–2,200) 1,172 (400–1,400) 480 (300–1,500) 914 (100–800) <0.6 (4.6–17) <0.02 (0.3–1.7) 6.80 (0.6–2.6) Recurrent respiratory infections IVIG
Pt. 4 14 F AICDA c.70C>Tb 
p.R24W
na na na na na na na na Recurrent respiratory infections na
Pt. 5 14/19a M CD40LG c.346+ 
4G>C
2,264 (800–1,800) 1,485 (400–1,200) 636 (200–800) 813 (100–500) 177 (100–700) 0.18 (6.4–19) 0.02 (0.6–3) 1.56 (0.6–3) na na
Pt. 6 4 M CD40LG c.487G>T; 
p.V163F
3,490 (1,200–4,000) 2,825 (600–2,200) 537 (400–1,400) 1,056 (300–1,500) 251 (100–800) <0.6 (5.3–19.6) <0.02 (0.4–2.6) 2.60 (0.5–3) Recurrent respiratory  
infections
IVIG, AZM
Pt. 7 3 M CD40LG p.T254P na na na na na na na na Neutropenia
Recurrent skin infection 
(impetigo)
na
Pt. 8 7 M CD40LG c.761C>T; 
p.T254M
4,275 (800–3,200) 3,198 (400–2,000) 844 (400–1,400) 791 (200–1,000) 192 (100–700) <0.45 (6.3–10) <0.04 (0.4–3) 3.75 (0.6–2.6) Recurrent media otitis
Hematuria by Proteus mirabilis
IVIG, TMP–SMZ
Pt. 9 30 M CD40LG p.C682T na Na na na na na na na Neutropenia
Aphthous stomatitis Warts
na
Pt. 10 2 M CD40LG c.585dupA; 
p.L195fs
na na na na na 3.25 (4.6–17) <0.07 (0.17–1.8) 1.22 (0.6–2.6) Candida esophagitis
Perianal abscess, ileocecal 
fistula, and multiple colic ulcers 
with perforation
BMT
IVIG, intravenous immunoglobulin; TMP–SMZ, trimethoprim/sulfamethoxazole; SCIG, subcutaneous immunoglobulin; AZM, azithromycin; BMT, bone marrow transplantation; na, data not available; nv, normal values.
In bold the abnormal values.
aPt.5 was analyzed twice, as a pediatric patient (14 years old) and as an adult patient (19 years old).
bHomozygous mutation.
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FIGURe 1 | Circulating Tfh and Tfr cells in an individual with CD40 deficiency compared to patients with CD40L and AICDA mutations. (a) Percentage of Tfh (gated 
on singlets → lymphocytes → CD3+CD19−CD14−CD8− → CD4+CD3+) in healthy pediatric (3–15 years, n = 7, HC_ped) and healthy adult (19–31 years, n = 9; 
HC_adult) healthy controls (HCs). (B) Representative flow cytometry plots for Tfh (CXCR5+FOXP3−), Tfr (CXCR5+FOXP3+), and T regulatory (Treg) (CXCR5−FOXP3+) 
cells, gated on singlets → lymphocytes → CD3+CD19−CD14−CD8− → CD4+CD3+ in hyper-IgM (HIGM) patients and age-matched HCs. (C–e) Percentage of Tfh (C), 
Tfr (D), and Treg (e) cells in pediatric [CD40 ligand (CD40L), n = 5; activation-induced cytidine deaminase (AID), n = 2; CD40, n = 1] and adult (CD40L, n = 2; AID, 
n = 1) HIGM patients, compared with age-matched HCs [same as in panel (a)]. (F) Tfh:Tfr ratio cells in pediatric and adult HIGM patients (AID, CD40L, and CD40 
deficiency, as indicated) compared with age-matched HCs. Bars: mean ± SEM. *p < 0.05 (Mann–Whitney test). Each dot represents one patient. Black & white 
squares represent longitudinal measurements of the same CD40L-deficient patient, collected at 14 and 19 years of age.
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with age-matched HCs, while children with AID deficiency had 
normal distribution of all cell subsets (Figures 1B–E).
The circulating Tfh:Tfr ratio provides important insights 
into the function and regulation of GC responses when evalu-
ated alongside the frequency of Tfh and Tfr. For example, an 
increased ratio of Tfh:Tfr was found in patients with Sjogren’s 
syndrome (22), suggesting the persistence of ongoing GC 
reactions. We observed that despite the alterations in Tfh and 
Tfr cells in CD40, CD40L and AID deficient pediatric patients, 
the ratio of Tfh:Tfr was similar to that observed in age-matched 
HCs (Figure 1F).
Circulating Tfh, Tfr and Treg cells were also reduced in 
adult CD40L-deficient patients compared with age-matched 
HCs (Figures 1B–E). While the Tfh:Tfr ratio was conserved in 
FIGURe 2 | Continued
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FIGURe 2 | Tfh cell activation phenotype in a patient with CD40 deficiency compared with patients with CD40L and AICDA mutations. (a) Percentage of PD-1+ and 
ICOS+ Tfh cells in peripheral blood of a pediatric (HC_ped) and adult (HC_adult) healthy controls (HCs) as described in Figure 1 (gated on singlets →  
lymphocytes → CD3+CD19−CD14−CD8− → CD4+CD3+ → CD4+CXCR5+). (B) Representative plots for PD-1+ and ICOS+ within Tfh cells in hyper-IgM (HIGM) patients 
and age-matched HCs. (C,D) Percentage of PD-1+ (C) and ICOS+ (D) Tfh cells in pediatric and adult HIGM patients and age-matched HCs (same as in Figure 1). 
(e) Percentage of PD-1+ICOS+ Tfh cells in pediatric and adult HIGM patients compared with age-matched HCs. (F,G) The proportion of Tfr (F) and T regulatory 
(Treg) (G) cells expressing PD-1 in pediatric and adult HIGM patients compared with age-matched HCs. (H) CXCL13 levels in the plasma of pediatric [CD40 ligand 
(CD40L), n = 2; activation-induced cytidine deaminase (AID), n = 1; CD40, n = 1] and adult HIGM patients (CD40L, n = 1; AID, n = 1) and age-matched HCs 
(pediatric HC, n = 25, adult HC n = 23). Bars: mean ± SEM. **p < 0.01 (Mann–Whitney test). Each dot represents one patient. Black & white squares represent 
longitudinal measurements of the same CD40L-deficient patient, collected at 14 and 19 years of age.
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one adult CD40L-deficient patient, it was reduced in the other 
one (Figure  1F). PBMCs from one CD40L-deficient patient 
were examined at a pediatric and an adult age (marked with 
bicolor). The percentage of Tfh and Tfr cells remained relatively 
stable during the follow-up (Figure 1C). On the contrary, Tfh 
cell frequency was increased in the single adult AID-deficient 
patient (Figure 1C), while Tfr and Treg cells were not affected 
(Figures 1D,E).
activation phenotype of tfh and tfr Cells 
in Human CD40 Deficiency
Next, we addressed the expression of PD-1 and ICOS, two 
molecules typically expressed by activated Tfh cells that cor-
relate with Tfh cell function (17–19). Given that the propor-
tion of Tfh cells expressing PD-1 and ICOS was higher in 
pediatric as compared with adult HCs (Figures 2A,B), clinical 
samples were compared with age-matched HCs. The propor-
tion of PD-1+ Tfh cells but not the PD-1 geometric mean 
fluorescence intensity (gMFI) was severely reduced in the 
CD40-deficient child but not the CD40L and AID-deficient 
children when compared with HCs (Figures  2B,C; Figure 
S1A in Supplementary Material). The proportions of ICOS+ 
and PD-1+ICOS+ Tfh cells but not ICOS gMFI were reduced 
in several patients affected by HIGM when compared with 
HCs, irrespective the genetic defect. However, the reduction 
in ICOS was more pronounced in the CD40-deficient child 
and some patients with CD40L deficiency (Figures  2B,D,E 
and data not shown).
Interestingly, the proportion Tfr and Treg cells expressing PD-1 
was elevated in the pediatric CD40-deficient patient (Figure 2G). 
Treg cells also expressed higher levels of PD-1 in this patient 
(Figure S1C in Supplementary Material). Instead, the propor-
tion and expression levels of PD-1 on Tfr and Treg cells in 
children with CD40L and AID deficiency were similar to those 
seen in HCs (Figures  2F,G; Figures S1B,C in Supplementary 
Material). The percentage of PD-1+ Tfr cells was slightly elevated 
in one adult CD40L-deficient and the adult AID-deficient 
patient as compared with HCs (Figures 2F,G).
Unexpectedly, plasma levels of CXCL13, a chemokine consi-
dered to be indicative of GC activity (23), were found elevated 
in the patient with CD40-deficiency, but were within the normal 
range in the CD40L-deficient patients (Figure  2H). Patients 
with AID deficiency had also elevated plasma levels of CXCL13 
compared with HCs, in line with the hyper-reactive GCs 
described in this disorder (17).
DIsCUssIoN
Our findings report the first phenotypic characterization of Tfh 
and Tfr in human CD40 deficiency and describe differences to 
other HIGM syndromes caused by mutations in CD40L and 
AICDA. The single patient with CD40 deficiency analyzed, 
showed a marked reduction in circulating Tfh and Tfr cells sug-
gesting that lack of CD40 signals contribute to an early demise 
of GCs in humans, similarly to mice (24). While the precise 
mechanism of CD40 signaling is poorly understood, CD40 
ligands on T  cells and follicular dendritic cells (FDCs) were 
shown to be essential for T-dependent and T-independent GC 
responses, respectively (25). In contrast to other forms of HIGM 
and particularly the CD40L deficiency, patients with CD40 
deficiency display a more severe clinical phenotype. It has been 
previously shown that CD40L is not the only ligand that can bind 
to CD40. A protein that binds activated complement 3b (C3b) 
and C4b, C4BP, on FDCs can also deliver signals to B cells via 
CD40 during T-cell independent responses (26). Possibly, the 
lack of these T-independent signals in human CD40 deficiency 
might have contributed in the aggravated clinical phenotype of 
this form of HIGM.
Antigen-specific interactions between Tfh cells and B  cells 
are required from the very first stage of their interaction to allow 
B-cell differentiation toward the GC fate and the maintenance of 
the GC response (27). B cells in return, provide signals for GC 
Tfh formation to Tfh cells suggesting that B cells and Tfh cells are 
mutually dependent on each other for their differentiation into 
GC B cells and GC Tfh cells, respectively (17–19, 28, 29). CD40L–
CD40 interactions along with integrin and SAP-dependent 
contacts between B and T cells were shown to be essential for this 
process (30–32). In agreement to previous reports, we found that 
patients with CD40L deficiency generated a small number of Tfh 
cells (21). Instead, circulating Tfh cells in a patient with CD40 
deficiency were heavily compromised. Although the blood is not 
the most suitable tissue to address the effect of CD40:CD40L 
signaling in Tfh development, our results suggest that other 
mechanisms might be able to compensate for the lack of CD40L. 
AICDA mutations on the other hand, increased the number of 
circulating Tfh cells in line with previous results supporting the 
notion that the reduced efficiency in generating highly mutated 
antibodies leads to enhanced GC reactions and increased Tfh cell 
development (16).
Both CD40L and CD40 deficiencies were characterized by 
normal or even elevated concentration of CXCL13 in the plasma. 
Tfh along with FDCs are the main source of CXCL13 in the B cell 
7Cicalese et al. Follicular Helper T Cell Subsets in HIGM
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follicles (23). Recently, a CXCR5−PD-1++ Tfh population was 
described in the tumor infiltrate of patients with breast cancer 
and the synovial fluid of patients with rheumatoid arthritis 
as an important source of CXCL13 (33). The percentage of 
CXCR5−PD-1++ cells was not increased in the blood of CD40- 
nor CD40L-deficient patients (data not included), suggesting the 
FDCs were the main source of CXCL13. Alternatively, the lack 
of “CXCL3 consumption” by GC Tfh and B cells might have led 
to an increase in the plasma CXCL13 levels in human CD40 and 
CD40L deficiency.
CoNCLUDING ReMaRKs
Although studies on additional CD40-deficient patients are nec-
essary, analysis of an individual with CD40 deficiency suggests 
that CD40 is possibly required for Tfh and Tfr development in 
humans. Compared with other genetically characterized forms 
of HIGM, i.e., due to mutations in CD40L and AICDA, patients 
with CD40 deficiency show a more severe clinical phenotype. 
According to our analyses, this could be partially explained by 
the more severe impairment of Tfh and Tfr cells. Longitudinal 
studies on a larger number of samples, i.e. blood and secondary 
lymphoid organs from patients with CD40 deficiency may offer 
useful insights in human Tfh biology, with important implica-
tions for understanding human GC development and potentially 
for the management of patients affected with HIGM or other 
primary immunodeficiencies.
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FIGURe s1 | Geometric mean fluorescence intensity (gMFI) of PD-1 in a 
patient with CD40 deficiency compared with patients with CD40L and AICDA 
mutations. (a–C) gMFI of PD-1 on Tfh (a), Tfr (B) and Treg cells (C) in 
pediatric and adult hyper-IgM (HIGM) patients compared with age-matched 
health controls (HCs) (same as in Figure 1). Bars: mean ± SEM. Each dot 
represents one patient. Black & white squares represent longitudinal 
measurements of the same CD40 ligand (CD40L)-deficient patient, collected at 
14 and 19 years of age.
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